Queens University Belfast has spun out its 100 th company with seed funding from a group of investors totalling £1.5 million.
The investment will go towards AilseVax, a company which specialises in identifying and developing therapeutic vaccines which work with the body to overcome cancer. It was formed as a spin-out from Queens and Trinity College Dublin and is made up with cancer experts from both universities.
Funding for the spin out has come from a range of investors including QUBIS, the commercialisation arm of Queen's University Belfast; Co Fund NI and TechStart NI as part of Invest Northern Ireland’s Access to Finance suite of funds; and Sapphire Capital, together with grants from Biomedical Catalyst, InnovateUK and Invest NI.
